Meridia Articles
Solvay costs and Meridia withdrawal take heavy toll on Abbott Labs 3rd-qtr 2010 results
21 October 2010
US FDA advisory panel split on keeping Abbott’s obesity drug Meridia on the market
16 September 2010
Abbott Labs gives up on vaccines unit sale, as no adequate bidders in sight; heart risks reported with obesity drug Meridia
6 September 2010
Bad day for slimming pill sibutramine, as EMEA calls for drug’s withdrawal and US FDA for “black box” warning
22 January 2010
EMEA starts sibutramine review, as FDA investigates Meridia
23 November 2009
Neurosearch obesity drug fares well in Ph II
10 November 2008
Danger to patients from weak US Rx system: CU
12 December 2005
Sanofi-Aventis' Acomplia will have huge impact on obesity market
6 September 2004
Obesity: "unmet needs create huge potential"
17 March 2003
Abbott gets approval for blockbuster candidate Humira in USA
6 January 2003
Abbott Labs warned over AD reporting
12 August 2002
CPMP backs safety of Abbott's sibutramine
8 July 2002
Abbott faces charges over "withheld data"
3 June 2002
Abbott posts strong revenue growth for 2001, but charges hit
21 January 2002
Abbott sales up 26% though earnings slip
11 October 2001
Abbott sales up 26% though earnings slip
10 October 2001
Abbott sales growth driven by pharma
13 July 2001
Knoll launches Reductil in UK
24 May 2001
Abbott gets European approval for Knoll's Reductil
5 April 2001
BASF sells pharma business to Abbott Labs for $6.9 billion in cash
15 December 2000
BASF wins positive opinion for Reductil in EU
22 November 2000
BASF excited about prospects for D2E7, as rumor mill talks of pharma
15 November 2000
CV benefits with Knoll's sibutramine
6 November 2000
Knoll's sibutramine still awaits Euro appros
11 January 2000
BASF profits hit badly by vitamins charge, Meridia sales stagnate
17 November 1999
Xenical, Meridia drive US antiobesity drugmarket
15 November 1999
BASF Pharma hoping to catch up with top pharmaceutical companies
23 September 1999
BASF Pharma first-half sales up 9% and speeding up
21 September 1999
US doctor charged over Internet Rxing offenses
13 July 1999
Further increase in Rxs for Roche's Xenical
2 June 1999
Xenical gets off to strong start in USA
13 May 1999
BASF profit warning
16 March 1999
New UK obesity guidelines highlight role of drugs
25 January 1999
First EU approval of Knoll's obesity drug
21 January 1999
Sepracor tops analysts' biotech stocks
20 January 1999
BASF Pharma Sales Driving Growth
12 November 1998
Fast Growth Seen For BASF's Pharma Unit
7 October 1998
First European Launch Of Xenical In September
4 August 1998
BASF Grows On All Fronts, Pharma Sales Up 21%
4 August 1998
NIH Obesity Guidelines Define Role Of Drugs
25 June 1998
BASF Makes Strong Start To 1998, Sales Up 7.4%
21 May 1998
BASF Not Looking To Sell Pharma Business
30 March 1998
Panel Split On Orlistat Approval For Obesity
16 March 1998
Knoll Starts Distribution Of Meridia For Obesity
13 February 1998
Knoll's High Hopes For Its Obesity Drug Sibutramine
15 January 1998
US Approval For Knoll's Obesity Drug Meridia
27 November 1997
BASF Profits Up But Pharma Growth Down
14 November 1997
Knoll's Meridia Approvable
25 September 1997
BASF Bullish On 1997 As Reflects On 1996
9 April 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
BASF/Knoll Considering More Investment In India
20 January 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
Knoll's Meridia Approvable In USA
18 November 1996
Roche Highlights Obesity Drug At R&D Conference
21 October 1996
Knoll's Sibutramine Rejected By US Panel
7 October 1996
Boots Buy Boosts BASF In 1996 First Half
2 September 1996
Redux Approved In The USA; Launch In June
6 May 1996
BASF To Introduce 4 New Drugs In 1996-7
8 April 1996
Knoll's Meridia
26 February 1996
Showing 1-79 of 79 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
